Unlocking the Complexities of Tumor-Associated Regulatory T Cells

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2018 Jan 10

PMID 29311383

Citations 39

Authors

Jaime L Chao

Peter A Savage

Affiliations

Soon will be listed here.

Abstract

Regulatory T (Treg) cells are found at elevated densities in many human cancers and are thought to be a major barrier to the generation of robust antitumor T cell responses. In this review, we discuss recent advances in the understanding of tumor-associated Treg cell diversity and function. Emerging evidence indicates that the transcriptional program of Treg cells infiltrating human cancers may represent a composite program blending a tissue-associated expression signature with an additional tumor-specific signature common to Treg cells from multiple cancer types. Studies in mouse models have defined unique molecular pathways required for Treg cell function in the tumor context that can be manipulated to selectively dampen intratumoral Treg cell activity. Finally, an expanding body of work has revealed diverse functions for Treg cells in nonlymphoid tissues that are unrelated to immune suppression, suggesting a need to explore functions of intratumoral Treg cells beyond the regulation of antitumor immunity.

Citing Articles

Regulatory T cells in the tumor microenvironment display a unique chromatin accessibility profile.

Dadey R, Cui J, Rajasundaram D, Yano H, Liu C, Cohen J Immunohorizons. 2025; 9(4).

PMID: 39965167 PMC: 11841976. DOI: 10.1093/immhor/vlae014.

PPARδ restrains the suppression function of intra-tumoral Tregs by limiting CIITA-MHC II expression.

Yang Q, Liang Y, Inoue-Hatanaka T, Koh Z, Ilkenhans N, Suman E bioRxiv. 2025; .

PMID: 39763816 PMC: 11702609. DOI: 10.1101/2024.12.16.628819.

Multiomics analysis of homologous recombination deficiency across cancer types.

Dong L, Li L, Zhu L, Xu F, Zhang R, Li Q Biomol Biomed. 2024; 25(1):71-81.

PMID: 39073402 PMC: 11647252. DOI: 10.17305/bb.2024.10448.

Unravelling infiltrating T-cell heterogeneity in kidney renal clear cell carcinoma: Integrative single-cell and spatial transcriptomic profiling.

Chen H, Zuo H, Huang J, Liu J, Jiang L, Jiang C J Cell Mol Med. 2024; 28(12):e18403.

PMID: 39031800 PMC: 11190954. DOI: 10.1111/jcmm.18403.

Iron capture through CD71 drives perinatal and tumor-associated Treg expansion.

Pacella I, Pinzon Grimaldos A, Rossi A, Tucci G, Zagaglioni M, Potenza E JCI Insight. 2024; 9(15).

PMID: 38954474 PMC: 11383606. DOI: 10.1172/jci.insight.167967.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Delgoffe G, Woo S, Turnis M, Gravano D, Guy C, Overacre A . Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 2013; 501(7466):252-6. PMC: 3867145. DOI: 10.1038/nature12428. View

Nowell C, Radtke F . Notch as a tumour suppressor. Nat Rev Cancer. 2017; 17(3):145-159. DOI: 10.1038/nrc.2016.145. View

Jang J, Hajdu C, Liot C, Miller G, Dustin M, Bar-Sagi D . Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell Rep. 2017; 20(3):558-571. PMC: 5649374. DOI: 10.1016/j.celrep.2017.06.062. View

Malchow S, Leventhal D, Nishi S, Fischer B, Shen L, Paner G . Aire-dependent thymic development of tumor-associated regulatory T cells. Science. 2013; 339(6124):1219-24. PMC: 3622085. DOI: 10.1126/science.1233913. View

Plitas G, Konopacki C, Wu K, Bos P, Morrow M, Putintseva E . Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 2016; 45(5):1122-1134. PMC: 5134901. DOI: 10.1016/j.immuni.2016.10.032. View

Sarris M, Andersen K, Randow F, Mayr L, Betz A . Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity. 2008; 28(3):402-13. PMC: 2726439. DOI: 10.1016/j.immuni.2008.01.012. View

Shang B, Liu Y, Jiang S, Liu Y . Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015; 5:15179. PMC: 4604472. DOI: 10.1038/srep15179. View

deLeeuw R, Kost S, Kakal J, Nelson B . The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012; 18(11):3022-9. DOI: 10.1158/1078-0432.CCR-11-3216. View

10.

Ladoire S, Martin F, Ghiringhelli F . Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother. 2011; 60(7):909-18. PMC: 11028605. DOI: 10.1007/s00262-011-1046-y. View

11.

Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

12.

Lobry C, Oh P, Aifantis I . Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med. 2011; 208(10):1931-5. PMC: 3182047. DOI: 10.1084/jem.20111855. View

13.

Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A . Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15(8):930-9. PMC: 3115752. DOI: 10.1038/nm.2002. View

14.

Kolodin D, van Panhuys N, Li C, Magnuson A, Cipolletta D, Miller C . Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab. 2015; 21(4):543-57. PMC: 4747251. DOI: 10.1016/j.cmet.2015.03.005. View

15.

Furness A, Vargas F, Peggs K, Quezada S . Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014; 35(7):290-8. DOI: 10.1016/j.it.2014.05.002. View

16.

Burzyn D, Benoist C, Mathis D . Regulatory T cells in nonlymphoid tissues. Nat Immunol. 2013; 14(10):1007-13. PMC: 4708287. DOI: 10.1038/ni.2683. View

17.

Smigiel K, Richards E, Srivastava S, Thomas K, Dudda J, Klonowski K . CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med. 2014; 211(1):121-36. PMC: 3892972. DOI: 10.1084/jem.20131142. View

18.

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View

19.

Campbell D, Koch M . Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011; 11(2):119-30. PMC: 3289970. DOI: 10.1038/nri2916. View

20.

Bulliard Y, Jolicoeur R, Windman M, Rue S, Ettenberg S, Knee D . Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013; 210(9):1685-93. PMC: 3754864. DOI: 10.1084/jem.20130573. View